It would not be wrong to quote that it would be a shock to world third largest drug maker – Sanofi-Aventis that the US District Court for the Central District of California has yet again invalidated its U.S. Reissue Patent No. RE38,743 (the ‘743 patent) on blockbuster blood thinner Lovenox, generically known as Enoxaparin Sodium which worth around $ 2 billion sales worldwide, after following Sanofi’s successful appeal in the US Court of Appeals which reversed the district court decision that had invalidated the ‘743 patent and returned back the case to the district court. The decision marks a major victory for generic manufactures --- Amphastar Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. which are being involved in legal fight since April 2003 following their Para IV challenge against the ‘743 patent.
No comments:
Post a Comment